Asian Fund for Cancer Research/LinkedIn
Dec 20, 2024, 15:43
Significant progress has been made in the research of YIV-906 – Asian Fund for Cancer Research
Asian Fund for Cancer Research shared a post on LinkedIn:
“In 2024, significant progress has been made in the research of YIV-906. YIV-906 is a first-of-its-kind botanical drug developed by Dr. Yongqi Zheng, a long-time AFCR-backed scientist at the Yale School of Medicine.
In preclinical models, YIV-906 significantly reduced gastrointestinal side effects in patients with rectal (GI) cancer undergoing chemotherapy and radiotherapy, enhancing the immune system’s response to tumors while protecting the patient’s digestive system.
Donations to support cancer research.
2024 scientific research project progress report.
Snapshot of Cancer Research Progress in 2024.”
More posts featuring Asian Fund for Cancer Research.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 16, 2025, 14:10
Aug 16, 2025, 14:01
Aug 16, 2025, 13:45
Aug 16, 2025, 13:15
Aug 16, 2025, 12:37
Aug 16, 2025, 11:57